Clinical Practice Surveillance of the Use of Herceptin Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)
Phase of Trial: Phase IV
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms HerSCin
- Sponsors Roche
- 07 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2018 Planned End Date changed from 30 Sep 2018 to 31 Jan 2019.
- 06 Dec 2018 Planned primary completion date changed from 30 Sep 2018 to 31 Jan 2019.